Leflunomide Tablet, Film Coated
Product Images NDC 68071-3763

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Leflunomide (NDC 68071-3763). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3763 9)

This text provides information about a medication called Leflunomide 10mg, including details such as the manufacturer, lot number, expiration date, description of the tablets, and instructions for storage. It also includes a warning to keep the medication out of reach of children and store it at a controlled temperature of 68-77°F.*

FDA Label Image

Image (D31d60f8 29ad 478b 85b2 Aabc27187368 01)

FDA Label Image

Image (D31d60f8 29ad 478b 85b2 Aabc27187368 02)

FDA Label Image

Image (D31d60f8 29ad 478b 85b2 Aabc27187368 03)

This text provides data on the percentage of participants who achieved an ACR 20 Responder status at the endpoint of three different trials involving various treatments for a specific duration of time. The treatments in the trials were Leflunomide (L), Methotrexate (M), Placebo (P), and Sulfasalazine (S). The duration of the trials was 12 months for Trial 1 and Trial 3, and 6 months for Trial 2. The data includes the number of responders for each treatment group in each trial, allowing for a comparison of treatment efficacy.*

FDA Label Image

Image (D31d60f8 29ad 478b 85b2 Aabc27187368 04)

This text presents data on ACR (American College of Rheumatology) responders over time in a clinical trial. The table shows the percentage of responders at months 3, 6, 9, and 12. The trial involves a combination of drugs, including Co, pL, MTX, and LEF. The data seems to have been analyzed using the Last Observation Carried Forward method.*

FDA Label Image

Image (D31d60f8 29ad 478b 85b2 Aabc27187368 05)

FDA Label Image

Image (D31d60f8 29ad 478b 85b2 Aabc27187368 06)

The text provides various numbers and data points related to measurements. It includes percentages like 0.2, 0.1, indicators of Improvement and Change in Functional Ability Measure. It also mentions different treatments like Leflunomide, Lethotrexate, and abbreviations such as L, MP, LS, P, M. Further details include a reference to the HAQ Disability Index and treatments like Placebo and Sulfasalazine.*

FDA Label Image

Image (D31d60f8 29ad 478b 85b2 Aabc27187368 07)

This text mentions that "LUPIN" and "i" are registered trademarks of Lupin Pharmaceuticals, Inc. These trademarks are likely used to distinguish Lupin Pharmaceuticals' products or services from others in the market.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.